African Women Breast Cancer Risk: Early Onset & Aggression
Unlocking Breast Cancer Mysteries: How specialized Cells Influence Early Disease Progression
Table of Contents
New research sheds light on the role of perivascular zone (PZP) cells in breast cancer development, revealing potential new avenues for targeted therapies.
A groundbreaking study from the University of Notre Dame is uncovering critical insights into the early stages of breast cancer, focusing on the intricate interactions between specialized cells and breast tissue. The research highlights how perivascular zone (PZP) cells, a type of cell found near blood vessels, may play a notable role in initiating and promoting the progression of breast cancer, particularly in women of African ancestry.
For years, scientists have been working to understand the complex cellular landscape that contributes to cancer development. This latest study,published in Nature Communications,identifies PZP cells as key players in the initial phases of breast cancer. These cells, when interacting with normal breast epithelial cells, can trigger changes that lead to the invasive nature characteristic of cancer.
the research team discovered that PZP cells can actively influence breast epithelial cells, prompting them to become more aggressive. This influence is exerted through several mechanisms:
Activation of Growth Pathways: A crucial finding is that PZP cells can activate a biological signaling protein known as AKT. AKT is frequently overactive in breast cancers and is known to promote cell growth and survival. The study demonstrates that PZP cells can trigger this activation in breast epithelial cells, thereby contributing to thier ability to invade surrounding tissues.
Secretion of Guiding Proteins: PZP cells also secrete and deposit specific proteins outside of themselves. These secreted proteins act as guides, directing the movement of breast epithelial cells as they begin to invade their surroundings.This process is a critical step in the metastatic cascade, were cancer cells spread from their original location.
These findings collectively underscore the multifaceted ways in which PZP cells can impact the early stages of breast cancer,potentially contributing substantially to the overall burden of the disease.
Targeting the AKT Pathway: A Promising Therapeutic Strategy
The study also explored the efficacy of a targeted breast cancer drug, capivasertib, which works by inhibiting the AKT protein. the results were highly encouraging: capivasertib markedly reduced the pro-cancerous effects of PZP cells on breast epithelial cells.This suggests that therapies targeting the AKT pathway could be a promising strategy for intervening in the early stages of breast cancer driven by PZP cell activity.
“It’s crucial to understand the biological and genetic differences within normal tissue as well as tumors among racial groups, as these variations could potentially influence treatment options and survival rates,” stated principal investigator Dr. Chandan D’Souza-Schorey, a professor of Biological Sciences at Notre Dame. “And consequently, in planning biomarker studies, cancer screenings or clinical trials, inclusivity is important.”
Advancing Research Through Collaboration and Innovation
The research team’s ability to conduct this in-depth study was facilitated by crucial collaborations and advanced methodologies.They partnered with the Susan G. Comment Tissue Bank at the indiana University Melvin and Bren Simon Comprehensive Cancer Center. This collaboration provided access to PZP cells and epithelial cells isolated from healthy breast tissues of both African and European ancestry.
To accurately mimic the complex cellular environment of the human body, these cell lines were cultured in a three-dimensional (3D) system.This innovative approach allows researchers to observe cellular behaviors and interactions in a more physiologically relevant context than conventional 2D cell cultures. The Notre Dame Integrated Imaging Facility also played a vital role, providing essential resources for visualizing and analyzing these intricate cellular processes.
The study’s co-authors include Madison Schmidtmann, victoria Elliott, James W. Clancy, and Zachary Schafer from Notre Dame, and Harikrishna Nakshatri from the IU Simon Comprehensive Cancer Center.This research not only deepens our understanding of breast cancer biology but also opens new avenues for developing more effective and inclusive diagnostic and therapeutic strategies. By identifying the specific roles of cells like PZP cells and validating targeted drug approaches, scientists are moving closer to personalized treatments that can improve outcomes for all patients.
**
Contact: Brandi Wampler, Associate Director of Media Relations, 574-631-2632, brandiwampler@nd.edu*